How to Get Rapamycin (Sirolimus) in Utah

What Rapamycin Is and Why Utah Residents Are Seeking It

Rapamycin (sirolimus) is an mTOR inhibitor the FDA approved in 1999 to prevent organ rejection after kidney transplantation. Over the past decade, a growing body of preclinical and early clinical research has positioned it as the most-studied pharmacological candidate for geroprotection. The PEARL trial (Aging Cell, 2024; N=150) found that topical rapamycin applied to dorsal hand skin improved multiple aging biomarkers over 8 months, adding to a broader evidence base suggesting that mTOR inhibition may slow selected aging processes [1].

Interest among Utah residents specifically has increased alongside the state's relatively permissive telehealth framework and active 503A compounding sector. Utah Code Ann. § 58-67-102 defines the practice of medicine broadly enough that a physician licensed in the state (or holding a state-recognized telehealth credential) may prescribe FDA-approved drugs for off-label indications when clinical judgment supports the decision. That legal architecture makes Utah one of the more accessible states for patients exploring rapamycin for longevity.

No large randomized trial has yet established rapamycin as a standard-of-care longevity drug. The prescribing is off-label. Patients should understand this distinction before seeking a prescription, and any clinician who does not explain it should raise a red flag.

Prescribing Pathways Available in Utah

There are two primary routes to a rapamycin prescription for Utah residents: telehealth consultations and traditional in-person visits. Both are legally valid.

Telehealth. Utah's Telehealth Act (Utah Code Ann. § 26-60) allows providers to establish a patient-provider relationship via synchronous audio-video visit. A physician licensed in Utah, or holding an appropriate interstate compact license, can evaluate a patient, review labs, and transmit a prescription to a Utah pharmacy, all without a prior in-person encounter. Several longevity-focused telehealth platforms now serve Utah directly, and turnaround from initial consultation to prescription transmission typically runs 3 to 7 business days.

In-person visits. Salt Lake City, Provo, and St. George each have integrative or longevity medicine clinics where physicians prescribe rapamycin off-label. An in-person visit may be preferred when the patient has complex comorbidities (e.g., hepatic impairment, active infection, prior organ transplant) that benefit from hands-on assessment.

Regardless of route, the prescriber must document a clinical rationale for off-label use. That documentation matters if a pharmacy or insurer later questions the prescription.

Who Can Prescribe Rapamycin in Utah (MD, DO, NP, PA)

Utah law permits MDs, DOs, nurse practitioners, and physician assistants to prescribe rapamycin [2]. The distinctions matter in practice.

MDs and DOs hold independent prescriptive authority. They can write and sign a rapamycin prescription without supervisory co-signatures. For off-label longevity prescriptions, this is the most straightforward path, and most telehealth longevity platforms employ or contract with MDs or DOs for this reason.

Nurse practitioners in Utah gained full practice authority under H.B. 86 (effective 2019), which removed the prior collaborative agreement requirement after 10,000 hours of supervised practice. An NP who has met this threshold can independently prescribe sirolimus. NPs who have not completed the transition period still require a collaborative agreement with a physician.

Physician assistants prescribe under a delegation of services agreement with a supervising physician. A PA can write a rapamycin prescription, but the supervising physician's name appears on the agreement, and some pharmacies may verify that relationship before dispensing.

Required Labs Before Starting Rapamycin in Utah

Every responsible prescriber will require baseline laboratory work before initiating sirolimus therapy. Rapamycin's mechanism of action (mTOR complex 1 inhibition) affects lipid metabolism, glucose homeostasis, and immune cell counts, so pre-treatment values establish a safety baseline.

The standard panel includes:

• Complete blood count (CBC) with differential. Rapamycin can cause mild leukopenia and thrombocytopenia. A baseline CBC identifies patients who already have low counts and may need closer monitoring or dose adjustment [3].
• Comprehensive metabolic panel (CMP). Hepatic transaminases (AST, ALT), creatinine, and electrolytes screen for liver and kidney dysfunction that could alter sirolimus pharmacokinetics.
• Fasting lipid panel. Hyperlipidemia is one of the most common side effects of sirolimus. The FDA label reports hypercholesterolemia in 43 to 46% of renal transplant patients on therapeutic doses [3]. Off-label longevity doses are lower, but a baseline lipid panel is non-negotiable.
• Fasting glucose and HbA1c. mTOR inhibition can impair insulin signaling. Patients with pre-diabetes (HbA1c 5.7 to 6.4%) require more frequent glucose monitoring during therapy.
• Sirolimus trough level (follow-up only). Not needed at baseline, but typically drawn 5 to 7 days after the first dose to confirm that weekly pulsed dosing does not produce sustained trough accumulation.

Most Utah-based telehealth platforms partner with Quest Diagnostics or Labcorp draw sites. Utah has more than 40 Quest patient service centers statewide, with concentrations along the Wasatch Front. Labs can also be ordered through any local hospital system.

How 503A Compounding Pharmacies Work in Utah

Utah permits 503A compounding pharmacies to prepare patient-specific prescriptions for sirolimus. This route is common for longevity dosing because commercial Rapamune tablets come in 0.5 mg and 1 mg strengths, while off-label protocols often call for 3 mg, 5 mg, or 6 mg capsules taken once weekly. A 503A pharmacy can compound a single capsule at the prescribed dose rather than requiring the patient to combine multiple tablets.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy must hold a valid state license (Utah DOPL pharmacy license), compound pursuant to a valid prescription for an identified individual patient, and use bulk drug substances that meet USP or NF standards. Utah's Division of Occupational and Professional Licensing (DOPL) oversees pharmacy licensing and inspects 503A facilities.

Several 503A pharmacies in Utah compound sirolimus and ship within the state. Out-of-state 503A pharmacies can also ship to Utah patients provided they are licensed in their home state and comply with Utah importation rules. Pricing for compounded sirolimus typically ranges from $1.50 to $4.00 per milligram, putting a 5 mg weekly dose at roughly $30 to $80 per month depending on the pharmacy and quantity ordered.

Commercial generic sirolimus (1 mg tablets) is also available at retail pharmacies like Intermountain Health pharmacies, Smith's, and Walgreens locations throughout Utah. GoodRx-type discount cards can bring 30 tablets of generic 1 mg sirolimus to approximately $30 to $60, though this requires the patient to take multiple tablets per dose.

Insurance, Medicaid, and Cost Considerations in Utah

Utah Medicaid does not cover rapamycin for off-label longevity use. Coverage exists only for FDA-approved indications, principally prophylaxis of organ transplant rejection and treatment of lymphangioleiomyomatosis (LAM) [4].

Private insurers in Utah (SelectHealth, Regence BlueCross BlueShield, Molina, University of Utah Health Plans) similarly restrict coverage to FDA-approved indications. An off-label prescription submitted to insurance will almost certainly trigger a prior authorization request, and that request will be denied absent a transplant or LAM diagnosis.

As a result, most patients pursuing rapamycin for longevity in Utah pay out of pocket. The practical cost depends on the dispensing route:

| Route | Approximate Monthly Cost (5 mg/week) | |---|---| | Generic sirolimus 1 mg (retail pharmacy, cash pay) | $30 to $60 | | 503A compounded capsule (5 mg each) | $30 to $80 | | Brand Rapamune 1 mg (retail, cash pay) | $900+ |

Brand Rapamune is rarely used for off-label longevity given the cost differential. Generic sirolimus or compounded capsules represent the overwhelming majority of fills.

Prior Authorization: What Utah Patients Need to Know

If you do submit a rapamycin prescription to insurance (for a covered indication), prior authorization in Utah typically requires the following documentation:

1. A letter of medical necessity from the prescribing physician.
2. The specific FDA-approved diagnosis code (ICD-10: T86.10 for kidney transplant rejection, D48.1 for LAM).
3. Labs demonstrating clinical appropriateness (sirolimus trough levels within target range for transplant dosing, typically 4 to 12 ng/mL).
4. Documented failure or contraindication to first-line agents (for transplant: tacrolimus, mycophenolate).

Utah follows CMS federal guidelines for Medicaid prior authorization. Private insurers set their own criteria, but the documentation above covers the standard request across most Utah payers. Turnaround is typically 48 to 72 hours for standard requests, with a mandatory 24-hour expedited pathway for urgent clinical situations.

For off-label longevity use, prior authorization is not a viable strategy. The claim will be denied, and the appeal will fail because no insurer recognizes longevity as a covered indication. Patients should plan for cash-pay from the outset.

Timeline: How Long Until You Receive Rapamycin in Utah

The process from decision to first dose typically spans 7 to 14 days. Here is a realistic breakdown:

Days 1 to 2: Schedule and complete a telehealth or in-person consultation. If labs are already in hand (drawn within the past 30 to 90 days, depending on the provider's requirements), the prescriber may send the prescription the same day.

Days 2 to 5: If labs are needed, draw at a local Quest or Labcorp site. Results return within 1 to 3 business days for standard panels.

Days 5 to 7: Prescriber reviews labs, documents clinical rationale, and transmits the prescription to the patient's chosen pharmacy.

Days 7 to 14: Pharmacy fills the prescription. Retail pharmacies with generic sirolimus in stock can fill within 24 to 48 hours. 503A compounding pharmacies typically require 3 to 7 business days for preparation and shipping.

Patients who have recent labs and choose a retail pharmacy with stock on hand can compress this timeline to as few as 5 days.

Safety Monitoring and Follow-Up

Rapamycin is not a "set and forget" prescription. The longevity medicine community has converged on a monitoring cadence that includes repeat labs at 4 to 6 weeks after initiation, then every 3 to 6 months during ongoing therapy [5].

Follow-up labs should include CBC with differential, lipid panel, fasting glucose, and a sirolimus trough level drawn immediately before the next weekly dose. The target trough for weekly pulsed longevity dosing is generally below 3 ng/mL, a level that suppresses mTORC1 without sustained mTORC2 inhibition that could worsen insulin resistance.

A 2014 meta-analysis of mTOR inhibitor side effects in transplant populations (N=21,993 across 44 trials) found that sirolimus increased the risk of new-onset diabetes by approximately 50% relative to calcineurin inhibitors [6]. Weekly pulsed dosing at lower concentrations may carry a different risk profile, but the absence of large RCTs in healthy adults means that metabolic monitoring remains mandatory.

Utah-based prescribers should also be aware of drug interactions. Sirolimus is metabolized by CYP3A4 and is a substrate of P-glycoprotein. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit juice) can increase sirolimus exposure severalfold. The FDA label lists a 10.9-fold increase in sirolimus AUC with concurrent ketoconazole [3].

Transferring an Existing Rapamycin Prescription to Utah

Patients relocating to Utah or visiting from another state can transfer an active sirolimus prescription to a Utah pharmacy. Utah follows the Uniform Controlled Substances Act, but sirolimus is not a controlled substance in any state, so transfer is straightforward.

The process: contact the receiving Utah pharmacy and provide the name and phone number of the originating pharmacy. The pharmacist-to-pharmacist transfer typically completes within one business day. For 503A compounded prescriptions, the new compounding pharmacy may need the original prescriber to send a new prescription directly, as compounded formulations are patient- and pharmacy-specific.

If your prescriber is not licensed in Utah, they cannot legally write new prescriptions for a Utah-resident patient (even for refills) unless they hold Utah licensure or an applicable interstate compact credential. You would need to establish care with a Utah-licensed provider.

The Evidence Base: Where Rapamycin for Longevity Stands in 2026

The preclinical case for rapamycin is among the strongest for any candidate geroprotective agent. The National Institute on Aging's Interventions Testing Program (ITP) has shown lifespan extension in genetically heterogeneous mice across multiple independent sites, with a median extension of approximately 9% in males and 14% in females at a dose of 14 ppm initiated at 20 months of age [7].

Translating mouse data to human dosing remains an active research question. The PEARL trial (2024), a randomized, double-blind, placebo-controlled study of topical rapamycin applied to hand skin in 150 participants over 8 months, reported improvements in clinical skin aging metrics [1]. While the PEARL trial used topical (not oral) rapamycin, it provides the first randomized evidence that mTOR inhibition can modify a measurable aging phenotype in humans.

The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) investigators noted that "rapamycin-treated skin showed statistically significant improvements in clinical grading, p<0.05 for multiple endpoints," though they emphasized the need for larger oral dosing trials before systemic anti-aging claims can be validated [1].

A separate trial, the AgelessRx RAPAMYCIN trial (registered as NCT04488601), is evaluating oral rapamycin for visceral fat, bone density, and other aging biomarkers. Results are expected to inform whether the oral longevity dosing protocols now common in clinical practice have measurable benefit.

The Endocrine Society has not issued guidelines on rapamycin for longevity. No major medical society has. This absence of guideline endorsement is the primary reason insurers decline coverage for off-label longevity use and why informed consent documentation is especially important.